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ABSTRACT 
Introduction: There have been several reported cases of lansoprazole- 
associated collagenous colitis (CC) reported in the literature but only 1 report- 
ed case of lansoprazole-associated lymphocytic olitis (LC) in the literature. 
Both CC and LC are considered inflammatory bowel diseases, but they are 
distinctly classified based on the condition of the colon, which is typically con- 
firmed through biopsy. 
Case summaries: A 52-year-old white male (Patient 1), with a height of 178 cm 
and weight of 75 kg, presented to Gazi University Hospital, Ankara, Turkey, 
with a 3-month istory of abdominal pain and nonbloody, watery diarrhea. The 
patient reported receiving PO lansoprazole 30 mg/d to treat heartburn ~1 week 
prior to the onset of diarrhea. The patient's medical history revealed that he 
did not have any preexisting conditions, other than gastroesophageal reflux 
disease (GERD) for which lansoprazole was prescribed. The medical history 
report also revealed that the patient was not receiving any concomitant medi- 
cations or treatments at the time. A colon biopsy confirmed LC. Additionally, 
a 43-year-old white female (Patient 2), with a height of 168 cm and weight of 61 
kg, presented to the same facility with a 6-month istory of nonbloody, watery 
diarrhea nd mild lower abdominal cramping. The patient reported that initial 
onset began -2 months after receiving a 10-day Helicobacter pylori eradication 
combination treatment regimen that included lansoprazole, amoxicillin, and 
clarithromycin, followed by lansoprazole monotherapy to treat GERD. The 
patient's medical history revealed no other concomitant medications were 
being adminstered atthe time. A colon biopsy confirmed LC. 
Discussion: A search of the literature using the MEDLINE database and all rel- 
evant English-language articles with key words lansoprazole and lymphocytic colitis, 
found that there were several cases of lansoprazole-associated CC reported and 
1 reported case of lansoprazole-associated LC. Histologic findings from labora- 
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tory tests and colon biopsies confirmed iagnoses of LC in both patients in this 
case report. Patient 1 presented with diarrhea nd cramping, which the patient 
reported had been ongoing for -3 months, following lansoprazole administra- 
tion. However, after lansoprazole was discontinued, the symptoms completely 
resolved within 7 days. Patient 2 presented with diarrhea nd cramping, which 
had been occurring for -6 months. That patient reported that initial onset com- 
menced -2 months after a 10-day H pylori eradication combination treatment 
regimen that included lansoprazole, amoxicillin, and clarithromycin, followed 
by lansoprazole monotherapy to treat GERD. However, after sulfasalazine (3 g/d) 
was prescribed for 2 months immediately upon diagnosis of LC, there was little 
improvement in the effort to control the diarrhea in this patient. After omepra- 
zole 20 mg/d was substituted for lansoprazole, the patient's diarrhea ceased. 
Follow-up sigmoidoscopy 2 months later revealed normal mucosa nd complete 
normalization ofhistologic findings. The patient remains diarrhea-free while on 
omeprazole. A causality assessment using the Naranjo adverse reaction algo- 
rithm produced scores of 6 for both patients, suggesting that LC was probably 
associated with lansoprazole treatment. 
Conclusions: Here we report 2 cases of LC in patients probably associated 
with the administration f lansoprazole treatment. Complete remission occurred 
after lansoprazole was discontinued. (Curt Ther Res Clin Exp. 2007;68:360-366) 
Copyright © 2007 Excerpta Medica, Inc. 
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INTRODUCTION 
All proton-pump inhibitors bind to the parietal cell proton pump covalently at 
cysteine 813 or 822. Lansoprazole, however, binds at cysteine 321.1,2 Binding of 
cysteine 321 inhibits colonic proton pumps, which might affect colonic secre- 
tion and pH, predisposing a patient o diarrhea nd microscopic olitis (MC). 
Lansoprazole decreases gastric acid secretion by inhibiting the proton pump 
of gastric parietal cells. 1 The drug has been used as monotherapy for peptic 
ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison 
syndrome, and in combination therapy for Helicobacter pylori eradication. 1,2Its 
acute and chronic use to treat hese disorders has been well tolerated, with few 
serious adverse events (AEs). 2 The most common AEs reported are diarrhea 
(4.1%), headache (2.9%), and nausea (2.6%). 3 In long-term (>12 months) clinical 
trials. 3-5 monitoring lansoprazole in the treatment for GERD, diarrhea was the 
most commonly reported AE. 
MC was first identified in 1980. 5 It is characterized by chronic watery, non- 
bloody diarrhea, abdominal pain or cramps, distention, nausea, fecal inconti- 
nence, and dehydration. MC includes collagenous colitis (CC) and lymphocytic 
colitis (LC). 6'7 Both CC and LC cause inflammation ofthe colon. Although inflam- 
matory bowel disease is the general term used to refer to diseases that cause 
inflammation of the intestines (eg, Crohn's disease, ulcerative colitis), CC and 
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LC are classified separately based on the distinct condition of the colon (ie, the 
presence of collagen in the lining of the colon [CC] and the number of white 
blood cells found between the cells of the large intestine [LC]). Specifically, LC 
is characterized by increased lymphocytic infiltration of the colonic epithelium 
and lamina propria. CC is characterized bynearly identical clinical and histologic 
features, but it also presents with chronic mucosal inflammation and a thickened 
subepithelial collagen band. 5,6 Because the radiologic and endoscopic assess- 
ments of the colon appear normal, diagnoses of CC and LC are usually confirmed 
by colon biopsies, which reveal the presence of microscopic abnormalities. 8 
A study by Read et al 9 that included a group of patients with chronic diar- 
rhea, found that the microscopic evaluation of biopsy material obtained from 
colonic mucosa had an increased number of intraepithelial lymphocytes. 7 
While the etiology of MC is not known, it is thought o be associated with a 
poorly-regulated pithelial immune response to luminal or epithelial antigens, 
including bile acids, toxins, and infectious agents. 1° MC has been associated 
with autoimmune diseases and drug exposure, predominantly NSAIDs, but 
salicylates, imvastatin, ticlopidine, ranitidine, carbamazepine, flutamide, gold 
salts, and lansoprazole as well. 1° The use of these drugs might be associated 
with the pathogenesis of MC by acting as triggers of colonic inflammation in 
genetically predisposed individuals and as an aid in the development or exac- 
erbation of diarrhea in a patient with underlying, undiagnosed MC. Therefore, 
in some patients, these drugs would be the most probable cause of diarrhea 
but not necessarily the probable cause of MC. In this case, these drugs might 
increase the possibility of early detection of MC. u 
We present 2 cases of LC associated with lansoprazole. In both cases, his- 
tologic tests were performed, and colon biopsies confirmed MC diagnoses. 
After lansoprazole was discontinued, cessation of diarrhea occurred in both 
patients. 
CASE SUMMARIES 
Pat ient 1 
A 52-year-old white male, with a height of 178 cm and weight of 75 kg, pre- 
sented to Gazi University Hospital, Ankara, Turkey, with a 3-month history of 
abdominal pain and nonbloody, watery diarrhea. The patient had received 
PO lansoprazole* 30 mg/d to treat heartburn -1 week prior to diarrhea onset. 
The patient's medical history did not reveal any preexisting conditions, other 
than GERD for which lansoprazole was prescribed. No concomitant medica- 
tions or treatments were being administered atthe time. Upon assessment, the 
patient reported having 6 to 7 bowel movements daily and intermittent lower 
abdominal cramping that was relieved with defecation. There was no associ- 
ated weight loss. Stool studies were negative for leukocytes, culture, ova and 
*Trademark: Lansor ® (Sanovel, Istanbul, Turkey). 
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parasites, and Clostridium difficile toxin. No occult blood was detected. Further 
diagnostic tests included a negative antiendomysial antibody test, normal iron 
studies (serum ferritin, serum iron, and serum-iron binding capacity), normal 
folate concentration, and normal thyroid-stimulating hormone concentration. 
Routine biochemistry parameters (blood-urea nitrogen, creatinine, glucose, 
alanine aminotransferase, aspartate aminotransferase, and electrolytes) were 
normal. A colonoscopy was performed and revealed normal mucosa. 
Histopathologic findings of 2 random biopsies were obtained from each 
colon section. Tissue was fixed in 10% formalin, preserved in paraffin wax, and 
stained with hematoxylin-eosin. The colon biopsies confirmed diagnosis of 
LC (defined by the presence of >20 lymphocyte/100 epithelial cells). The sub- 
epithelial collagen plate was of normal thickness. There were no architectural 
distortions, crypt abscesses, or granulomas found or identified. There was no 
evidence of dysplasia or malignancy, and no microorganisms were identified. 
Discontinuation f lansoprazole corresponded with complete cessation of diar- 
rhea and abdominal cramping within 7 days. After 2 months, a repeat colonos- 
copy with biopsies from each colon section found no evidence of LC. 
Patient 2 
A 43-year-old white female patient, with a height of 168 cm and weight of 61 kg, 
presented to Gazi University Hospital, Ankara, Turkey, with a 6-month history 
of nonbloody, watery diarrhea nd mild lower abdominal cramping. The patient 
reported that the symptoms commenced -2 months after receiving a 10-day 
Hpylori eradication treatment regimen that included lansoprazole (30 mg BID), 
amoxicillin (1 mg BID), and clarithromycin (500 mg BID), followed by monother- 
apy with PO lansoprazole 30 mg/d to treat GERD. The patient's medical history 
did not reveal concomitant medications or treatments being administered at
the time. The patient reported that the diarrhea nd cramping had been ongo- 
ing for -6 months. She was having 8 to 10 nonbloody, watery bowel movements 
daily, some of which interrupted sleeping patterns. The patient also reported 
an 8-kg weight loss. Routine blood tests included complete blood count (hemo- 
globin, hematocrit, platelet, white blood cell), complete metabolic profile, amy- 
lase and lipase activities, erythrocyte sedimentation rate, calcium concentra- 
tion, and thyroid function tests (TSH, FT3, FT4). All laboratory findings were 
unremarkable or negative. Stool tests were negative for ova and parasites and 
for C difficile toxin. An upper endoscopy revealed GERD. Duodenal biopsy find- 
ings were unremarkable, and colonoscopy was grossly normal. 
Two random biopsies were obtained from each colonic section. Tissue was 
fixed in 10% formalin, preserved in paraffin wax, and stained with hematoxylin- 
eosin. Histopathologic findings of the colon biopsies revealed a marked 
increase in the number of intraepithelial lymphocytes (defined by the presence 
of >20 lymphocytes/100 epithelial cells). The subepithelial collagen plate was of 
normal thickness. In addition, the lamina propria was infiltrated with lympho- 
cytes and plasma cells, confirming a diagnosis of LC. 
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Sulfasalazine treatment was administered immediately upon LC diagnosis. After 
2 months of treatment with sulfasalazine 3 g/d, there was little improvement in
the effort to control the diarrhea in this patient. However, after PO omeprazole* 
20 mg/d was substituted for lansoprazole, the diarrhea ceased within 5 days. 
Follow-up sigmoidoscopy 2 months later revealed normal mucosa nd normal his- 
tologic findings. The patient remained free of diarrhea on omeprazole. 
DISCUSSION 
The etiology of MC (both CC and LC) is unknown but is suspected to be multi- 
factorial. Several hypotheses have been suggested, including drug effect, 
immune dysfunction, autoimmunity, and infection. Among these, drug con- 
sumption has been suggested to play an important role. To date, >17 drugs have 
been reported to be associated with the onset of MC, including NSAIDs, and, 
rarely, salicylates, imvastatin, ticlopidine, ranitidine, and carbamazepine. 12-14 
Drugs that can induce or exacerbate MC need to be identified because the con- 
dition impacts quality of life, can be life-threatening, and might require the use 
of expensive and potentially toxic treatments. 11 
There have been multiple reports of drug-associated MC, which include: LC 
secondary to ranitidine treatment implicating histamine2-receptor blockers in 
persistent histologic features of both LC and CC14,15; an association between 
NSAID use and LC and CC16'17; a case of simvastatin-induced CC18; ticlopidine- 
induced colitis19; LC likely attributable toa vinca alkaloid2°; chronic diarrhea con- 
sistent with LC in a patient who ingested tardyferon21; and 1 case report of CC 
associated with lansoprazole. 22 Once drug-induced diarrhea issuspected, iarrhea 
is typically treated by discontinuing the administration of the drug. Although 
the pathophysiology remains to be determined, possible mechanisms include bac- 
terial overgrowth, alteration of intestinal pH, intestinal dysmotility, and bile salt 
abnormalities a a consequence of colonic proton-pump inhibition. 23 
The mechanism oflansoprazole-associated MC is unknown but might involve 
toxic or immunologic factors. Lansoprazole might have a direct toxic effect on 
colonocytes, or indirect toxic metabolites may be involved after the drug is 
hepatically biotransformed. 1,22,24 Alternatively, lansoprazole might stimulate an 
inappropriate immune reaction in certain predisposed individuals. 24 
All proton-pump inhibitors act on parietal cells by binding to cysteine resi- 
dues 813 and 822 via 2 disulfhydryl bonds. 25 Lansoprazole, however, is unique 
in its ability to also inhibit colonic proton pumps by binding to cysteine residue 
321 via 3 disulfhydryl bonds. 26 Inhibition of colonic proton pumps might have 
an effect on colonic secretion and pH, which could, in turn, affect bile salt 
solubility and action. These factors might explain the diarrheagenic potential 
of lansoprazole. Omeprazole, however, does not inhibit colonic proton pumps 
because it does not bind to cysteine 321. In Patient 2, substituting omeprazole 
*Trademark: Omeprol ® (llsan, Kocael, Turkey). 
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for lansoprazole did not lead to recurrent  diarrhea. In Patient 1, cessat ion of 
d iarrhea and the absence of LC on a follow-up s igmoidoscopy after discontinu- 
ation of lansoprazole suggest an adverse drug reaction. 
A causal i ty assessment  using the Naranjo adverse drug reaction algorithm 27 
produced scores of 6 for both patients, suggesting that LC was probably  associ-  
ated with lansoprazole treatment.  
CONCLUSIONS 
Lansoprazole was probably  associated with MC in these 2 pat ients.  Dis- 
cont inuing the drug reversed  the abnormal i ty  in this dif f icult-to-treat con- 
dition. MC should be cons idered  in pat ients  who develop watery  d ia r rhea  
while receiv ing lansoprazo le .  
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